Aneuploidy Rates in Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study

Blastocyst Aneuploidy Rates From Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study

Pregnancy rates for women over 35 years old are significantly lower when compared to younger women. One of the causes for this decrease is believed to be chromosomal aneuploidy. Chromosomal aneuploidy is a natural phenomena and occurs in women of every age and has been implicated in spontaneous miscarriages, and preimplantation embryo wastage (Hassold and Hunt, 2001).

As maternal age increases, so too does the incidence of chromosomal aneuploidy. Embryo quality from older patients undergoing IVF tends to be reduced and associated with higher rates of chromosomal abnormalities when compared to good quality embryos (Munne et al., 1995).

Chromosomal aneuploidy derives from the improper segregation of chromosomes during preimplantation development. The process of segregation, or mitosis, includes synthesis of the complete genome, equal division of chromosomes to opposite poles by the spindle apparatus, and separation of the two cells by cytokinesis, yielding two chromosomally identical cells. The entire process of cellular and genetic replication requires energy in the form of adenosine tri phosphate (ATP). ATP is mainly produced in mitochondria in the process known as the electron transport chain (ETC). There are many important molecules required for ATP production, CoQ10 can act as the appropriate carrier of electrons through the ETC. When a deficiency in CoQ10 is present, ATP production is decreased resulting in aneuploidy (Bentov et al., 2013). Similarly, research has shown that chromosome alignment and spindle formation are affected by mtDNA copy number (Ge et al., 2012). It has also been shown that the transfer of ooplasm from young, healthy oocyte donors into oocytes of women with repeated embryonic failure has result in children with subsequent mitochondrial heteroplasmy (Cohen et al., 1998).

CoQ10 concentrations have been shown to decrease as age increases (Bentov et al., 2011). Consequently, the decrease in CoQ10 concentrations seen in older women may cause an increase in chromosomal aneuploidy in subsequent embryos (Bentov et al., 2013). In this pilot study, we test the hypothesis that the supplementation of CoQ10 prior to an IVF cycle can increase mitochondrial DNA activity and possibly decrease chromosomal aneuploidy in AMA patients.

Study Overview

• Status: Completed
• Conditions: Aneuploidy; Mitochondrial DNA
• Intervention / Treatment: Dietary supplement: Placebo; Dietary supplement: CoQ10

Detailed Description

Brief Summary

• Study Type: Interventional
• Enrollment (Actual): 21
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • North Carolina
    • Charlotte, North Carolina, United States, 28207
      • Reach

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 36 years to 42 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. 36-42 years old
2. Must present with an AMH level ≤2.0 ng/mL
3. 1st cycle of IVF treatment
4. Antral follicle count >5 and <20

Exclusion Criteria:

1. BMI >39
2. Active smoker
3. Blood serum baseline level of CoQ10 ≥2.20 µg/mL
4. Prior use of CoQ10
5. Type II diabetes mellitus

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: sugar pill; Group 2 will receive a placebo of CoQ10	Dietary supplement: Placebo; This is a placebo which will be administered daily to the patient for 3 months prior to IVF.
Experimental: CoQ10; Patients will be divided into 2 groups. Group 1 will be treated with an oral supplement, 125 mg/twice daily of CoQ10 (NeoQ10, Theralogix, Rockville, Maryland, USA) for 3 months prior to IVF. This dosage will equate to a Cmax of 6.89 ug/ml (Liu and Artmann, 2009).	Dietary supplement: CoQ10; This is a dietary supplement which will be administered daily to the patient for 3 months prior to IVF

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Embryo mitochondrial DNA (mtDNA)	mtDNA levels will be assesed from day 5 or day 6 blastocysts

Secondary Outcome Measures

Outcome Measure	Time Frame
preimplantation chromosomal aneuploidy	aneuploidy rates will be measured utilizing SNP array from day 5 and day 6 blastocysts

Collaborators and Investigators

• Sponsor: Reproductive Endocrinology Associates of Charlotte
• Investigators: Principal Investigator: Jack L Crain, MD, Reproductive Endocrinology Associates of Charlotte

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2014
• Primary Completion (Actual): May 1, 2018
• Study Completion (Actual): May 1, 2018

Study Registration Dates

• First Submitted: April 14, 2014
• First Submitted That Met QC Criteria: April 17, 2014
• First Posted (Estimate): April 21, 2014

Study Record Updates

• Last Update Posted (Actual): May 4, 2018
• Last Update Submitted That Met QC Criteria: May 3, 2018
• Last Verified: May 1, 2018

More Information

Terms related to this study

• Keywords: IVF; aneuploidy; blastocyst; mtDNA; COQ10
• Additional Relevant MeSH Terms: Pathologic Processes; Chromosome Aberrations; Aneuploidy; Physiological Effects of Drugs; Micronutrients; Vitamins; Coenzyme Q10
• Other Study ID Numbers: REACh-002